- The author estimates that in 2016, there were 288,800 incident cases of small cell lung cancer (SCLC) worldwide, and forecasts that number to increase to 316,300 incident cases by 2025.
- Northern America is estimated to have the highest disease incidence (10.26 per 100,000 people), while Africa has the lowest incidence (0.42 per 100,000 people).
- Owing to the rapid disease progression and the development of drug resistance during the disease course, treatment of SCLC remains very challenging.
- Therapies in mid and late-stage development for SCLC focus on a variety of targets. The majority of the drugs in mid-to-latestage development for SCLC are administered via the intravenous route, with the remainder being oral, intramuscular, and subcutaneous.
- Novartis’s Hycamtin (topotecan) and Aeterna Zentaris’s lobaplatin, which target topoisomerase I and DNA, respectively, are the only marketed drugs for SCLC. Hycamtin is widely approved, while lobaplatin is only approved in China.
- High impact upcoming events for drugs in the SCLC space include topline Phase II and Iib, and Phase III trial results. Licensing and asset acquisition activity involving SCLC drugs has been weak during 201217, with only nine deals over this time period. The $356m license agreement between CytRx and NantCell for the exclusive rights to develop and market aldoxorubicin, was the largest deal during 201217.
- Opdivo’s peak sales potential surpasses its competitors, although the majority of forecast sales are for indications other than small cell lung cancer.
- The clinical trials distribution across Phase I-IV indicates that the majority of the drugs are in early and mid phases of development, with 88% of trials in Phase I-II, and only 12% in Phase III-IV.
- The US has a substantial lead in the number of small cell lung cancer clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
- Pfizer has carried out the most Phase III trials in small cell lung cancer, with 8 trials, followed by GlaxoSmithKline and BristolMyers Squibb which have each sponsored 6 Phase III trials.
KEY UPCOMING EVENTS
LICENSING AND ASSET ACQUISITION DEALS
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
OncoMed Trying To Regroup After Cancer Stem Cell Pipeline Failures
List of Figures
Figure 1: Trends in Incident Cases of Small Cell Lung Cancer, 2016-25
Figure 2: Pipeline drugs for SCLC in the US
Figure 3: Pipeline drugs for SCLC, by company
Figure 4: Pipeline drugs for SCLC, by drug type
Figure 5: Pipeline drugs for SCLC, by classification
Figure 6: Key upcoming events in SCLC
Figure 7: Licensing and asset acquisition deals in SCLC
Figure 8: Parent patents in SCLC
Figure 9: Clinical trials in SCLC
Figure 10: Top 10 drugs for clinical trials in SCLC
Figure 11: Top 10 companies for clinical trials in SCLC
Figure 12: Trial locations in SCLC
Figure 13: SCLC trials status
Figure 14: SCLC trial sponsors, by phase
List of Tables
Table 1: Incident Cases of Small Cell Lung Cancer, 2016-25
Table 2: Incidence Rates of Small Cell Lung Cancer, 2016-25
Table 3: Marketed drugs for SCLC
Table 4: Approvals by country for SCLC
Table 5: Pipeline drugs for SCLC in the US